Background: Rapamycin is an immunosuppressive drug with potent antifibrotic activity. We evaluated the effect of rapamycin on murine adriamycin nephropathy, a model of progressive glomerulosclerosis and tubulointerstitial fibrosis. Methods: Adriamycin nephropathy was induced in Balb/c mice by a single intravenous injection of adriamycin. The mice were treated orally with either saline or rapamycin, beginning at the time of adriamycin injection or rapamycin starting 1 week after adriamycin injection. The mice were sacrificed 6 weeks after adriamycin injection. Results: Saline-treated mice developed massive proteinuria and impaired renal function. Kidney sections from saline-treated mice showed marked focal segmental glomerulosclerosis, tubular dilation with protein cast deposition, interstitial fibrosis, and numerous infiltrating macrophages and T lymphocytes. The intrarenal expression of Collagen I and RANTES was also increased. In contrast, both groups of rapamycin-treated mice had markedly reduced proteinuria and preserved renal function, with only mild histological abnormalities. The intrarenal expression of Collagen I and RANTES was reduced, concomitant with a significant reduction in interstitial inflammatory cell infiltration. Conclusions: Rapamycin is effective in attenuating the glomerular and tubulointerstitial abnormalities in adriamycin nephropathy. The beneficial effects of rapamycin are mediated, at least in part, through reduced RANTES expression and inflammatory cell infiltration.

Keywords:
Focal segmental glomerulosclerosis, Interstitial fibrosis, Proteinuria, Glomerulosclerosis
1.
Liu Y: Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213–217.
2.
Daskalakis N, Winn MP: Focal and segmental glomerulosclerosis: varying biologic mechanisms underlie a final histopathologic end point. Semin Nephrol 2006;26:89–94.
3.
Jaber BL, Madias NE: Progression of chronic kidney disease: can it be prevented or arrested? Am J Med 2005;118:1323–1330.
4.
Ruggenenti P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004;24:158–167.
5.
Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335–340.
6.
MacDonald AS; RAPAMUNE Global Study Group: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271–280.
7.
Stallone G, Infante B, Schena A, et al: Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755–3762.
8.
Bonegio RG, Fuhro, R, Wang, Z, et al: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063–2072.
9.
Wu MJ, Wen MC, Chiu YT, et al: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006;69:2029–2036.
10.
Wang Y, Wang YP, Tay YC, et al: Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000;58:1797–1804.
11.
Fogo AB: Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003;23:161–171.
12.
Yung S, Woods A, Chan TM, Davies M, Williams JD, Couchman JR: Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization. FASEB J 2001;15:1631–1633.
13.
Vielhauer V, Berning E, Eis V, et al: CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004;66:2264–2278.
14.
Wu H, Wang Y, Tay YC, et al: DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 2005;67:2178–2186.
15.
Rangan GK, Coombes JD: Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2007;22:2175–2182.
16.
Hochegger K, Jansky GL, Soleiman A, Wolf AM, et al: Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008;19:1520–1509.
17.
Kawaguchi M, Yamada M, Wada H, et al: Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. Toxicology 1992;72:329–340.
18.
Rangan GK, Wang Y, Tay YC, et al: Cytokine gene expression in adriamycin nephropathy: effects of antioxidant nuclear factor κB inhibitors in established disease. Nephron 2000;86:482–490.
19.
Zheng G, Wang Y, Mahajan D, et al: The role of tubulointerstitial inflammation. Kidney Int 2005;67(suppl 94):S96–S100.
20.
Krensky AM, Ahn YT: Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007;3:164–170.
21.
Zoja C, Benigni A, Remuzzi G: Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 1999;7:420–428.
22.
Brabcova I, Kotsch K, Hribova P, et al: Intrarenal gene expression of proinflammatory chemokines and cytokines in chronic proteinuric glomerulopathies. Physiol Res 2007;56:221–226.
23.
Zoja C, Donadelli R, Colleoni S, et al: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998;53:1608–1615.
24.
Romano MF, Avellino R, Petrella A, et al: Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40:2829–2836.
25.
Wang Y, Wang YP, Tay YC, et al: Role of CD8+ cells in the progression of murine adriamycin nephropathy. Kidney Int 2001;59:941–949.
26.
Wang Y, Mahajan D, Tay YC, et al: Partial depletion of macrophages by ED7 reduces renal injury in adriamycin nephropathy. Nephrology (Carlton) 2005;10:470–477.
27.
Wang Y, Wang Y, Feng X, et al: Depletion of CD4+ T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney Int 2001;59:975–984.
28.
Mahajan D, Wang Y, Qin X, et al: CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 2006;17:2731–2741.
29.
Wu H, Wang YM, Wang Y, et al: Depletion of γδ T cells exacerbates murine adriamycin nephropathy. J Am Soc Nephrol 2007;18:1180–1189.
30.
Naumovic R, Jovovic D, Basta-Jovanovic G, Miloradovic Z, Mihailovic-Stanojevic N, et al: Effects of rapamycin on active Heymann nephritis. Am J Nephrol 2007;27:379–389.
31.
Diekmann F, Rovira J, Carreras J, Arellano EM, Banon-Maneus E, et al: Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007;18:2653–2660.
32.
Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1:109–116.
33.
Cho ME, Hurley JK, Kopp JB: Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49:310–317.
34.
Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E: Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215–220.
35.
Rangan GK: Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 2006;29:1153–1161.
36.
Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C: Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005;5:2849–2861.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.